Dyne Therapeutics announced on Monday that its experimental drug targeting Duchenne muscular dystrophy (DMD) has successfully met its primary endpoint in a late-stage clinical trial. This...
Dyne Therapeutics announced on October 16, 2023, that its experimental drug for **Duchenne muscular dystrophy** (DMD) has successfully met the primary endpoint in a late-stage clinical...